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Abstract
Background: Currently definitive 5-fluorouracil (5-FU)/cisplatin (CDDP) -based chemotherapy is recognized as one
of the most promising treatments for esophageal cancer. A series of studies performed found genetic
polymorphisms and the plasma concentration of 5-FU to be predictive of acute severe toxicities and clinical
response. Genetic polymorphisms of tumor necrosis factor (TNF) -a and its surface receptors, TNFRSF1A and
TNFRSF1B have been examined in terms of susceptibility to various cancers. In this study, genetic polymorphisms of
TNFRSF1B gene were evaluated Japanese esophageal squamous cell carcinoma (ESCC) patients treated with the
definitive 5-FU/CDDP-based chemoradiotherapy and their predictive values of prognosis or severe acute toxicities
were assessed.
Methods: Forty-six patients with ESCC were treated with the definitive 5-FU/CDDP-based chemoradiotherapy, one
course of which consisted of the continuous infusion of 5-FU for days 1-5 and 8-12, the infusion of CDDP on days
1 and 8, and the radiation at 2 Gy/day on days 1-5, 8-12, and 15-19, with a second course repeated after 2-week
interval. Genetic polymorphisms of a TNF-a receptor TNFRSF1B gene were determined by a TaqMan® MGB probe-
based polymerase chain reaction.
Results: The genotype of TNFSR1B A1466G, but not M196R/T587G or C1493T, was found to be predictive of clinical
response, i.e., a complete response or not (p = 0.040). Clinical response was predicted by tumor size (p = 0,002),
lymph node metastasis (p = 0.007), distant metastasis (p = 0.001) and disease stage (p < 0.001), but TNFRSF1B
A1466G genotype was independent of these factors.
Conclusions: Genetic polymorphism of TNFRSF1B A1466G was found to be predictive response in Japanese ESCC
patients with a definitive 5-FU/CDDP-based chemoradiotherapy. Further clinical investigation with a large number
of patients or experiments in vitro should be performed to assess the predictive value of TNFRSF1B A1466G
genotype after chemoradiotherapy.
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A clinical report published in 1999, the RTOG (Radia-
tion Therapy Oncology Group) 85-01 trial involving 134
patients with T1-3, N0-1 and M0 esophageal cancer, is
of great interest in terms of clinical outcome because it
demonstrated a 5-year survival rate of 26% [1]. This
treatment consists of infusions of 5-fluorouracil (5-FU)
and cisplatin (CDDP), and concurrent radiation, without
pre- or post-surgical resection. Simultaneously in Japan,
a modified version was proposed by Ohtsu and his co-
workers for advanced metastatic esophageal cancer [2,3].
Two independent clinical investigations have shown
curative potential using this regimen for unresectable
esophageal squamous cell carcinoma (ESCC) of T4 or
M1a [2,3]. A long-term evaluation of efficacy and toxi-
city with 139 patients revealed a complete response
(CR) rate of 56%, along with a 5-year survival rate of
29% [4,5]. Currently, definitive 5-FU/CDDP-based che-
moradiotherapy is recognized as one of the most pro-
mising treatments for esophageal cancer [6]. A series of
studies performed to find a marker predictive of clinical
outcome after treatment with a definitive 5-FU/CDDP-
based chemoradiotherapy found a genetic polymorph-
ism, G-1154A, of vascular endothelial growth factor to
be a predictor of severe acute leukopenia and cheilitis,
and the plasma concentration of 5-FU to be predictive
of clinical response [7-9].
Tumor necrosis factor (TNF)-a, a proinflammatory
cytokine, plays a key role in the pathogenesis of inflam-
matory diseases. Its biological effects are elicited by
binding to its two cognate cell surface receptors,
TNFRSF1A/TNFR1 (p55/60) and TNFRSF1B/TNFR2
(p75/80), both of which are involved in increasing
expression of other cytokines and immuno-regulatory
molecules through the activation of nuclear factor B.
Through extensive examinations of expression and func-
tion, some genetic variations have been shown to
explain inter-individual variation. Single nucleotide poly-
morphisms (SNPs) in the TNF-a, TNFRSF1A and
TNFRSF1B genes have been identified, however func-
tional data pertaining to these polymorphisms in scarce.
Nonetheless, the putative role of these polymorphisms
in disease susceptibility has been examined in genetic
association studies of various inflammatory disorders,
including Crohn’s disease [10-13], ulcerative colitis
[10,11,14], systemic lupus erythematosus [15-17] and
rheumatoid arthritis [18,19]. More recently, given that
cancer progression is preceded by a long period of sub-
clinical inflammation [20-22], the genetic polymorph-
isms of TNF-a, TNFRSF1A and TNFRSF1B have been
examined in terms of susceptibility to various cancers
[23-28]. In this study, genetic polymorphisms of the
TNFRSF1B gene, M196R/T587G, A1466G and C1493T,
were evaluated in Japanese ESCC patients treated with a
definitive 5-FU/CDDP-based chemoradiotherapy, and
their predictive values of prognosis or severe acute toxi-
cities were assessed. To our knowledge, this is the first
paper to report that the TNFRSF1B genotype is predic-
tive of the clinical efficacy of cancer chemoradiotherapy.
Methods
Patients
Forty-six male ESCC patients were enrolled in this study
based on the following criteria: 1) ESCC treated with a
definitive 5-FU/CDDP-based chemoradiotherapy at
Kobe University Hospital, Japan, from August 2002 to
June 2006; 2) clinical stage T1 to T4, N0 or N1, and M0
or M1a according to the International Union Against
Cancer tumor-node-metastasis (TNM) classification; 3)
age less than 85 years; 4) an Eastern Cooperative Oncol-
ogy Group performance status of 0 to 2; 5) adequate
bone marrow, renal, and hepatic function; 6) no prior
chemotherapy; 7) no severe medical complications; and
8) no other active malignancies (except early cancer).
The tumors were histologically confirmed to be primary,
and no patients with recurrence were included in this
study. Written informed consent was obtained from all
participants prior to enrollment. This study was con-
ducted with the authorization of the institutional review
board and followed the medical research council guide-
lines of Kobe University.
Protocol
The protocol is presented in Figure 1. A course consisted
of the continuous infusion of 5-FU at 400 mg/m
2/day for
days 1-5 and 8-12, the infusion of CDDP at 40 mg/m2/
day on days 1 and 8, and the radiation at 2 Gy/day on
days 1 to 5, 8 to 12, and 15 to 19, with a second course
repeated after a 2-week interval [2,3]. If disease progres-
sion/recurrence was observed, either salvage surgery,
endoscopic treatment, or another regimen of chemother-
apy was scheduled.
Genotyping
Genomic DNA was isolated from whole blood with a Taq-
Man® Sample-to-SNP™ k i t( A p p l i e dB i o s y s t e m s ,F o s t e r
City, CA, USA) according to the manufacturer’s directions.
Genetic polymorphisms of TNFRSF1B; M196R/T587G,
A1466G and C1493T, were determined by a TaqMan®
MGB probe-based polymerase chain reaction (PCR) using
the StepOne™ real-time PCR system (Applied Biosystems)
and pre-manufactured TaqMan® SNP genotyping assays
C_8861232_20 (M196R/T587G, rs1061622), C_8861229_10
(A1466G, rs1061624) and C_8861228_20 (C1493T, rs3397)
(Applied Biosystems). The PCR was carried out according
to the manufacturer’s protocol. For each set of reactions,
Kuwahara et al. Journal of Experimental & Clinical Cancer Research 2010, 29:100
http://www.jeccr.com/content/29/1/100
Page 2 of 6DNA of cases and controls was taken and a negative con-
trol containing H2O instead of DNA was added to check
for contamination.
Clinical response
The clinical response was evaluated according to the
method reported previously [2-5]. Briefly, a CR was
defined as the complete disappearance of all measur-
able and assessable disease at the first evaluation,
which was performed 1 month after the completion of
chemoradiotherapy to determine whether the disease
had progressed. The clinical response was evaluated
by endoscopy and chest and abdominal computed
tomography (CT) scans in each course. A CR at the
primary site was evaluated by endoscopic examination
when all of the following criteria were satisfied on
observation of the entire esophagus: 1) disappearance
of the tumor lesion; 2) disappearance of ulceration
(slough); and 3) absence of cancer cells in biopsy spe-
cimens. If small nodes of 1 cm or less were detected
on CT scans, the recovery was defined as an “uncer-
tain CR” after confirmation of no progression for at
least 3 months. An “uncertain CR” w a si n c l u d e da sa
CR when calculating the CR rate. When these criteria
were not satisfied, a non-CR was assigned. The exis-
tence of erosion, a granular protruded lesion, an ulcer
scar, and 1.2 w/v% iodine/glycerin-voiding lesions did
not prevent an evaluation of CR. The evaluations were
performed every month for the first 3 months, and
when the criteria for CR were not satisfied at 3
months, the result was changed to non-CR. Follow-up
evaluations were performed thereafter every 3 months
for 3 years by endoscopy and CT scan. After 3 years,
patients were seen every 6 months. During the follow-
up period, a routine course of physical examinations
and clinical laboratory tests was performed to check
the patient’sh e a l t h .
Severe acute toxicities
Definitive 5-FU/CDDP-based chemoradiotherapy is
associated with acute toxicities; leucopenia, anemia,
thrombocytopenia, nausea/vomiting, diarrhea, mucositis
(including stomatitis), esophagitis, and renal dysfunction
[2-5]. Here, severe acute leucopenia, stomatitis, and
cheilitis were subjected to analysis. Toxicity was evalu-
ated using criteria defined by the Japan Clinical Oncol-
ogy Group [29]. These criteria were based on the
National Cancer Institute Common Toxicity Criteria.
Toxicity was assessed on a 2 to 3-day basis during the
chemoradiotherapy and subsequent hospitalization per-
iod and on every visit after the completion of chemora-
diotherapy. Episodes of leucopenia, stomatitis, and
cheilitis during the first 2 courses and subsequent
2 weeks (until day 70) were recorded as acute toxicities
and those of grade 3 or more as severe acute toxicities.
Survival after the chemoradiotherapy
The survival period was defined as the time from the
date of treatment initiation to that of death from any
causes or to the last date of confirmation of survival.
Survival data were updated on December 31, 2006, and
the 2-year survival rate was assessed using the data for
36 patients.
Data analysis and statistics
All values reported are the mean ± standard deviation
(SD). The unpaired Student’s t-test/Welch’st e s to rM a n n -
Whitney’s U test was used for two-group comparisons of
the concentrations. Fisher’se x a c tt e s tw a su s e df o rt h ea n a -
lysis of contingency tables. The difference of overall
1 1st course 2nd course
1st
cycle
2nd
cycle
1st
cycle
2nd
cycle
5-FU
2 weeks
CDDP
40 mg/m2/day
400 mg/m2/day
Radiation
2Gy/day
40 m mg/m /day
22 8 15
Treatment day
36 43 50 1
Figure 1 Protocol of a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy. One course of treatment consisted of protracted
venous infusions of 5-FU (400 mg/m
2/day, days 1-5 and 8-12) and CDDP (40 mg/m
2/day, days 1 and 8), and radiation (2 Gy/day, days 1-5, 8-12,
and 15-19), with a second course (days 36-56) repeated after a 2-week interval.
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less than 0.05 (two tailed) were considered to be significant.
Results
Demographic and clinicopathologic characteristics of the
46 ESCC patients are summarized in Table 1. The ratio of
T1/T2/T3/T4 was 15/6/14/12, that of N0/N1 was 21/25,
and that of M0/M1a was 39/7, resulting in a stage I/II/III/
IVa ratio of 12/10/17/7. The CR rate was 47.8% (22/46),
and 2-year survival rate was 50.0% (18/36). The clinical
response, i.e., CR or non-CR, was predicted by T class
(p = 0.002), N class (p = 0.007), M class (p = 0.001) and
disease stage (p < 0.001). Episodes of severe acute leucope-
nia, stomatitis and cheilitis occurred in 39.1% (18/46),
13.0% (6/46) and 15.2% (7/46) of cases, respectively and
no associations were foundw i t ht h ed e m o g r a p h i ca n d
clinicopathologic characteristics.
Table 2 indicates the association of the TNFRSF1B
genetic polymorphisms M196R/T587G, A1466G and
C1493T with clinical response in the ESCC patients.
TNFRSF1B A1466G genotype was predictive of clinical
response (p = 0.040), whereas M196R/T587G and
C1493T were not. No effects of the TNFRSF1B geno-
types were found for TNM classes and disease stage
(data not shown). Figure 2 shows the association of clin-
ical response with overall survival of the patients. The
patients with CR survived markedly longer than the
non-CR patients (p < 0.001, Log-rank test). However,
the 2-year survival rate was 25.0%, 60.0% and 50.0% in
the patients with the TNFRSF1B genotypes AA
1466,
AG
1466 and GG
1466, and the effect of TNFRSF1B
A1466G genotype on the overall survival was not signifi-
cant (Log-rank test). In addition, the effects of
TNFRSF1B M196R/T587G, A1466G and C1493T
genotypes were not found for severe acute leucopenia,
stomatitis or cheilitis (data not shown).
Discussion
The TNFRSF1B gene on chromosome 1 at p36 (IBD7)
consists of 10 exons and encodes 415 amino acids,
whereas the TNFRSF1A gene at 12p13 (IBD2) consists
of 10 exons and encodes 455 amino acids. TNFRSF1A is
Table 1 Demographic and clinicopathologic
characteristics of Japanese patients with esophageal
squamous cell carcinoma.
Age, yr 64.6 ± 7.2 (range 48-78)
Height, cm 164.2 ± 6.2 (range 152-
180)
Weight, kg 56.7 ± 9.6 (33-79)
Male/Female 46/0
Performance status, 0/1/2/unknown 23/19/3/1
Differentiation, well/moderate/poor/
unknown
7/27/6/6
T1/T2/T3/T4 15/6/14/12
N0/N1 21/25
M0/M1a 39/7
Stage I/II/III/IVa 12/10/17/7
The values are the mean ± SD. Noncervical primary tumours with positive
supraclavicular lymphnodes were defined as M1a.
Table 2 Effects of TNFRSF1B polymorphisms on clinical
response in Japanese patients with esophageal
squamous cell carcinoma.
Complete
response
N=2 2
Not complete
response
N=2 4
p
M196R/T587G
(rs1061622)
TT 15 21 0.354
TG 5 2
GG 2 1
T 35 44 0.135
G9 4
A1466G
(rs1061624)
AA 2 10 0.040
AG 15 10
GG 5 4
A 19 30 0.094
G2 5 1 8
C1493T
(rs3397)
CC 9 12 0.787
CT 9 9
TT 4 3
C 27 33 0.515
T1 7 1 5
Figure 2 Association of clinical response with overall survival
Japanese patients with esophageal squamous cell carcinoma.
Line: CR, Dotted line: non-CR. The patients with CR survived
extensively longer than the non-CR patients (p < 0.001, Log-rank
test).
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lar death domain, and TNFRSF1B is thought to be
involved in ligand passing, thereby regulating the asso-
ciation of TNF-a with TNFRSF1A. TNFRSF1A is widely
expressed, whereas TNFRSF1B is predominantly
expressed in cells of the hematopoietic lineage. Several
clinical investigations have been conducted to assess the
predictive value of the genetic polymorphisms TNF-a
G-308A, TNFRSF1A A36G and G-609T, and TNFRSF1B
M196R/T587G, A1466G (or A1663G) and C1493T (or
C1690T) regarding susceptibility to various inflamma-
tory disorders [10-19], and recently, to cancer [23-28].
As for TNFRSF1B, the SNP M196R/T587G has proved
predictive of Crohn’s disease [13], systemic lupus erythe-
matosus [15-17] and rheumatoid arthritis [18].
TNFRSF1B A1466G is not associated with Crohn’sd i s -
ease [13], but the haplotype 1466A-1493T might be
important [11]. Recently, TNFRSF1B C1493T has been
found to be a risk factor of tobacco-related oral carci-
noma [28].
In this study, it was demonstrated that the TNFRSF1B
A1466G genotype was a predictive factor of clinical
response to treatment with a definitive 5-FU/CDDP-
based chemoradiotherapy in Japanese ESCC patients.
The TNFRSF1B G-allele at position 1466 is predictive of
clinical response, whereas no such association was
found for M196R/T587G or C1493T (Table 2). Clinical
response was evaluated 1 month after the completion of
the chemoradiotherapy, and a CR was defined as the
complete disappearance of all measurable and assessable
disease. Clinical response was determined by T class (an
index of tumor size, p = 0.002), N class (lymph node
metastasis, p = 0.007), M class (distant metastasis, p =
0.001) and disease stage (p < 0.001), but TNFRSF1B
A1466G genotype was independent of these factors.
Clinical response was significantly associated with
overall survival (Figure 2), however, TNFRSF1B A1466G
genotype had no effect on the overall survival, presum-
ably because it was not associated with death within 1
year after the completion of chemoradiotherapy. There
is no report on the function of this polymorphism but it
has been reported that higher expression levels of
TNFRSF1B gene in colorectal cancer specimens from
responding patients were observed compared with those
from non-responding patients [30]. Thus, the poly-
morphism-dependent clinical response might be due to
the polymorphism-dependent expression levels, although
further studies are needed.
Conclusions
Genetic polymorphisms of the TNFRSF1B gene, M196R/
T587G, A1466G and C1493T, were evaluated in Japa-
nese ESCC patients treated with a definitive 5-FU/
CDDP-based chemoradiotherapy. It was found that
A1466G, but not M196R/T587G or C1493T, was a pre-
dictive factor of clinical response to chemoradiotherapy.
Clinical response was predicted by TNM classes and
disease stage, but A1466G genotype was independent of
these factors. Further clinical investigation with a large
number of patients or experiments in vitro should be
performed to assess the predictive value of TNFRSF1B
A1466G genotype after chemoradiotherapy.
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